RFX5

Across TCGA pan-cancer cohorts, RFX5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RFX5 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RFX5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RFX5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where RFX5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.942	0.736	<.001	78	view →
CCRCC	OS	Quartile	II,III,IV	0.853	0.510	.001	36	view →
UCEC	DFS	Quartile	III,IV	0.409	1.000	.040	4	view →
PDAC	DFS	Tertile	III,IV	0.758	0.336	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RFX5–LUAD (OS)

Open the LUAD breakdown →